Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 202

1.

[Genetic alterations and biomarkers for glioma].

Nagane M.

Brain Nerve. 2012 May;64(5):537-48. Review. Japanese.

PMID:
22570067
[PubMed - indexed for MEDLINE]
2.

The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.

von Deimling A, Korshunov A, Hartmann C.

Brain Pathol. 2011 Jan;21(1):74-87. doi: 10.1111/j.1750-3639.2010.00454.x. Review.

PMID:
21129061
[PubMed - indexed for MEDLINE]
3.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
[PubMed - indexed for MEDLINE]
4.

Molecular diagnostics of gliomas: the clinical perspective.

Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M.

Acta Neuropathol. 2010 Nov;120(5):585-92. doi: 10.1007/s00401-010-0750-6. Epub 2010 Sep 23. Review.

PMID:
20862485
[PubMed - indexed for MEDLINE]
5.

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.

PMID:
20975057
[PubMed - indexed for MEDLINE]
6.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

PMID:
20160062
[PubMed - indexed for MEDLINE]
Free Article
7.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.

Neuro Oncol. 2012 Sep;14 Suppl 4:iv100-8. doi: 10.1093/neuonc/nos206. Review.

PMID:
23095825
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.

Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.

Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.

PMID:
23429602
[PubMed - indexed for MEDLINE]
Free Article
9.

Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.

Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.

Neuro Oncol. 2012 Jan;14(1):109-16. doi: 10.1093/neuonc/nor185. Epub 2011 Oct 27.

PMID:
22039037
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Diagnostic and prognostic markers in gliomas.

Ducray F, El Hallani S, Idbaih A.

Curr Opin Oncol. 2009 Nov;21(6):537-42. doi: 10.1097/CCO.0b013e32833065a7. Review.

PMID:
19667985
[PubMed - indexed for MEDLINE]
11.

Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.

Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.

Neurol Med Chir (Tokyo). 2007 Aug;47(8):341-9; discussion 350.

PMID:
17721049
[PubMed - indexed for MEDLINE]
Free Article
12.

Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.

Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC.

Neuropathol Appl Neurobiol. 2009 Aug;35(4):367-79. doi: 10.1111/j.1365-2990.2008.01002.x. Epub 2008 Nov 18.

PMID:
19019173
[PubMed - indexed for MEDLINE]
13.

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.

Ochsenbein AF, Schubert AD, Vassella E, Mariani L.

J Neurooncol. 2011 Jun;103(2):343-51. doi: 10.1007/s11060-010-0395-2. Epub 2010 Sep 21.

PMID:
20857319
[PubMed - indexed for MEDLINE]
14.

[Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].

Wick W, Weller M.

Nervenarzt. 2010 Aug;81(8):928-30, 932-5. doi: 10.1007/s00115-010-2956-1. Review. German.

PMID:
20635074
[PubMed - indexed for MEDLINE]
15.

Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.

Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC.

Clin Cancer Res. 2009 Nov 1;15(21):6683-93. doi: 10.1158/1078-0432.CCR-08-2801. Epub 2009 Oct 27.

PMID:
19861461
[PubMed - indexed for MEDLINE]
Free Article
16.

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.

J Clin Oncol. 2009 Dec 10;27(35):5874-80. doi: 10.1200/JCO.2009.23.6497. Epub 2009 Nov 9. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708.

PMID:
19901110
[PubMed - indexed for MEDLINE]
17.

Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, Chandler C, Brazil L, Sadler G, Beaney R, Sibtain N, King A, Bodi I, Jones C, Ashkan K, Al-Sarraj S.

Neuro Oncol. 2013 Dec;15(12):1635-43. doi: 10.1093/neuonc/not125. Epub 2013 Oct 24.

PMID:
24158110
[PubMed - indexed for MEDLINE]
18.

Molecular genetic markers as predictors of response to chemotherapy in gliomas.

Idbaih A, Omuro A, Ducray F, Hoang-Xuan K.

Curr Opin Oncol. 2007 Nov;19(6):606-11. Review.

PMID:
17906460
[PubMed - indexed for MEDLINE]
19.

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.

PMID:
19636000
[PubMed - indexed for MEDLINE]
20.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.

PMID:
22136423
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk